Table 1.
Number of identified proteins/peptides due to PTM-sensitive MS/MS search for control and GBM plasma samples.
Fig 1.
Sequence coverage for various protein PTMs.
Identification by Mascot of ≥ 3 peptides per protein. The adjusted inverse normalized values are displayed as a violin plot, comparing distributions between control and GBM samples. Horizontal bars indicate the mean (dashed line) and median (solid line) values for each group.
Table 2.
Enrichment of plasma Alpha-2-HS-glycoprotein (FETUA_HUMAN, 367 aa) sequence coverage with peptides assembled from MS/MS search for phosphorylated peptides.
Fig 2.
MS/MS spectra of non-modified (A) and phosphomodified (B) peptide DSSPDSAEDVR (2+) of alpha-2-HS-glycoprotein (FETUA_HUMAN) GBM plasma.
Monoisotopic mass of neutral peptide Mr (calc) 1,592.62. Variable modification S7–Phospho (ST) with neutral loss 97.98. [y(10)] in a non-modified peptide was not detected.
Table 3.
List of modified peptides of FDA-approved proteins identified in control and GBM plasma via PTM-sensitive MS/MS search (Mascot).
Fig 3.
Changes in the fractions of PTM peptides of FDA-approved plasma biomarkers in GBM compared to control.
Table 4.
GBM-negative and GBM-positive patterns’ counted for FDA-approved plasma proteins.